ArticleJournal of the American Chemical Society2019
Elucidation and Structural Modeling of CD71 as a Molecular Target for Cell-Specific Aptamer Binding.
Article in Journal of the American Chemical Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 148 citations in OpenAlex.
- Ligand-Defined Interfacial Chemistry Enables Instant and Sequence-General DNA Chemisorption on Gold Nanoparticles Toward Label-Free SERS With Single-Base Resolution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Copper homeostasis and cuproptosis: molecular mechanisms and therapeutic opportunities.Molecular biomedicine · 2026Review
- Transferrin receptor 1: an emerging therapeutic target in cancer beyond iron metabolism.Cancer cell international · 2026Review
- Preliminary assessment of biodistribution and targeting of the fluorescent molecular probe Cy7-SYL3C in an EpCAM-positive colorectal cancer mouse model.Scientific reports · 2026Article
- Article
- Cu-doped dendritic biodegradable nanoplatforms for augmenting cuproptosis and tumor-starvation therapy through mitochondrial metabolic cascade modulation.Materials today. Bio · 2025Article
- Disruption of the Nucleolin-CXCR4 interaction by the DNA aptamer HY-4 halts colorectal cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Elevated expression of transferrin receptor-1 in pancreatic cancer: clinical implications and prognostic significance.Clinical and experimental medicine · 2025Article
- Functional aptamer evolution-enabled elucidation of a melanoma migration-related bioactive epitope.Acta pharmaceutica Sinica. B · 2025Article
- Development and validation of an intratumoral-peritumoral deep transfer learning fusion model for differentiating BI-RADS 3-4 breast nodules.Gland surgery · 2025Article
- Solid lipid nanoparticles in pancreatic cancer treatment.BJC reports · 2025Review
- Molecular Programming Design of Glyconucleic Acid Aptamer with High Stability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Bidirectional effects of morphine on pancreatic cancer progression via the p38/JNK pathway.Scientific reports · 2024Article
- Article
- Aptamer Technologies in Neuroscience, Neuro-Diagnostics and Neuro-Medicine Development.Molecules (Basel, Switzerland) · 2024Review
- Assessing Aptamer-Analyte Binding Kinetics by Microfluidic Fluorescence Microscopy.Sensors and actuators. B, Chemical · 2024Article
- Cell Membrane-Anchored DNA Nanoinhibitor for Inhibition of Receptor Tyrosine Kinase Signaling Pathways via Steric Hindrance and Lysosome-Induced Protein Degradation.ACS pharmacology & translational science · 2024Article
- High spatial-resolved heat manipulating membrane heterogeneity alters cellular migration and signaling.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The effect of GelDex-S58 hydrogel on anti-conjunctival scarring after glaucoma filtration surgery.iScience · 2023Article
- Single-nucleobase resolution of a surface energy transfer nanoruler forChemical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
Pancreatic cancer is a highly lethal malignancy associated with tissues of the pancreas. Early diagnosis and effective treatment are crucial to improving the survival rate of patients with pancreatic cancer. In a previous study, we employed the cell-SELEX strategy to obtain an ssDNA aptamer termed XQ-2d with high binding affinity for pancreatic cancer. Here, we first identify CD71 as the XQ-2d-binding target. We found that knockdown of CD71 abolished the binding of XQ-2d and that the binding affinity of XQ-2d is associated with membrane-bound CD71, rather than total CD71 levels. Competitive analysis revealed that XQ-2d shares the same binding site on CD71 with transferrin (Tf), but not anti-CD71 antibody. We then used a surface energy transfer (SET) nanoruler to measure the distance between the binding sites of XQ-2d and anti-CD71 antibody, and it was about 15 nm. Furthermore, we did molecular dynamics simulation to clarify that the spatial structure of XQ-2d and Tf competitively binding to CD71. We also engineered XQ-2d-mediated targeted therapy for pancreatic cancer, using an XQ-2d-based complex for loading doxorubicin (Dox). Because CD71 is overexpressed not only in pancreatic cancer but also in a variety of tumors, our work provides a systematic novel way of studying a potential biomarker and also promising tools for cancer diagnosis and therapy, opening new doors for effective cancer theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.